Testosterone Replacement Therapy Guidelines

Introduction to Testosterone Replacement Therapy

The American College of Physicians recommends testosterone replacement therapy for patients with hypogonadism, with transdermal gels generally preferred as first-line therapy due to superior cardiovascular safety and more stable testosterone levels 1

Testosterone gels provide the most stable day-to-day serum testosterone concentrations and have demonstrated better cardiovascular safety compared to injections 1
Available gel formulations include 1% testosterone gel, 1.62% testosterone gel, and 2% testosterone gel, with varying application sites and dosages 2
Peak serum levels occur 6-8 hours after application of transdermal gels 2
Long-acting injections, such as testosterone enanthate or cypionate, are administered intramuscularly every 2 weeks, with peak levels occurring 2-5 days post-injection 2, 3, 4
Extra-long-acting injections, such as testosterone undecanoate, provide less fluctuation in testosterone levels and are administered every 10 weeks 2

The Endocrine Society recommends starting with transdermal gel for most patients due to its superior cardiovascular safety profile and more stable testosterone levels 1
Switch to intramuscular injections when maximum transdermal dose fails to achieve adequate serum testosterone levels, cost is prohibitive, or patient has reduced disease-management skills or resources 1, 3, 4

The American Urological Association recommends confirming diagnosis with serum testosterone measurements on at least two separate mornings, with both values below normal range 3, 5
Starting dose for 1.62% gel is 40.5 mg daily, and for injections is 100-200 mg every 2 weeks 2
Baseline testing required includes PSA level, hematocrit or hemoglobin, digital rectal examination, voiding symptoms assessment, and sleep apnea history 3, 5
Follow-up schedule includes first visit at 1-2 months, measure testosterone levels at 2-3 months after initiation or dose change, and visits every 3-6 months for first year, then yearly 2, 3, 5

General principle is to adjust dose based on clinical response and serum testosterone levels, with increase in dose if suboptimal response with low-normal levels 3, 4

Hematologic monitoring is required, with temporary withholding of therapy, reduction of dose, or phlebotomy if hematocrit rises above reference range 3, 4
Prostate cancer surveillance is necessary, with negative prostate biopsy before initiating therapy in men with abnormal digital rectal exam or elevated PSA 3, 4
Cardiovascular considerations include possible increased risk of heart attack and stroke, particularly with injections 1, 2

Formulation-specific issues include gel transfer risk, injection site reactions, and patch irritation 1, 5
General adverse effects include breast tenderness and swelling, testicular atrophy and compromised fertility, fluid retention, acne, oily skin, increased body hair, flushing, and sleep apnea exacerbation 1, 5

Patient preference plays a significant role in formulation selection, with 71% of patients preferring topical gel over injection or patch after >1 month use, and 53% initially choosing injections due to lower cost 1
Annual cost differential is substantial, with $2,135 for transdermal vs $156 for intramuscular formulations 1